8,858 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Norden Group LLC

Norden Group LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,858 shares of the medical device company’s stock, valued at approximately $689,000.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Jennison Associates LLC grew its position in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. lifted its stake in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD bought a new position in DexCom during the fourth quarter worth about $96,507,000. Westfield Capital Management Co. LP lifted its stake in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in DexCom by 182.7% during the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after purchasing an additional 739,000 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock worth $3,309,794 over the last 90 days. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $85.99 on Tuesday. The business’s 50-day simple moving average is $84.82 and its 200 day simple moving average is $76.85. The stock has a market cap of $33.60 billion, a price-to-earnings ratio of 60.13, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on DXCM shares. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company raised their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.